腹膜后脂肪肉瘤的临床诊断和治疗研究进展  

Research Progress of Clinical Diagnosis and Treatment of Retroperitoneal Liposarcoma

作　　者：马超[1] 李沛雨[1] MA Chao;LI Peiyu(Department of General Surgery,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院普通外科,北京100853

出　　处：《医学综述》2018年第12期2350-2355,共6页Medical Recapitulate

摘　　要：腹膜后脂肪肉瘤(RPLPS)是一种十分罕见的恶性肿瘤,起源于间叶组织。但其临床症状不典型,不易早期发现;同时肿瘤复发率高,对化疗和放疗不敏感。除手术治疗外尚缺乏有效的治疗手段,患者预后差。近年来随着影像学技术的不断发展,术前充分的影像学评估提高了肿瘤的完整切除率,延长了患者术后复发的时间。基于对RPLPS发病机制研究的不断深入,分子靶向治疗逐渐应用于临床。其通过阻止特定基因的突变和特定分子通路中的靶蛋白合成,来干扰细胞癌变和肿瘤增生,在提高治疗精准性的同时减少不良反应发生。未来,这些靶基因或靶蛋白不仅有助于更好地评估肿瘤的发生、发展和预后,还有望大幅延长患者的生存期。Retroperitoneal liposarcoma（ RPLPS） is a very rare malignant tumor originating from mesenchymal tissue.However,its clinical symptoms are not typical and it＇s difficult to detect at the early stage. Meanwhile,the recurrence rate is high,and it is not sensitive to chemotherapy and radiotherapy. Except surgical treatment,there is still no effective treatment,and the prognosis is poor. In recent years,with the continuous development of imaging technology,preoperative imaging evaluation has improved the complete resection rate and prolonged the postoperative recurrence time. Based on the in-depth study of the pathogenesis of RPLPS,molecular targeted therapy is gradually applied in clinical. It interferes with cell carcinogenesis and tumor proliferation by blocking mutation of specific genes and targeting protein synthesis in specific molecular pathways,reducing adverse effects while improving therapeutic accuracy. In the future,these target genes or target proteins will not only help to better evaluate the genesis,development and prognosis of tumors,but also greatly prolong the survival time of the patients.

关 键 词：腹膜后肿瘤 脂肪肉瘤 诊断 治疗 

分 类 号：R735.4[医药卫生—肿瘤]